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Objectives: To refresh clinical diagnostic dilemmas in patients presenting with symptoms resembling to those of
parkinsonism, to report rare association of colon cancer and paraneoplastic stiff person syndrome (SPS), and to
draw attention on the possible correlation of capecitabine therapy with worsening of paraneoplastic SPS.
Methods: Case report of the patient with paraneoplastic SPS due to colon cancer that was misdiagnosed as
idiopathic Parkinson’s disease (iPD), whose symptoms worsened after beginning adjuvant capecitabine
chemotherapy.
Results: We describe a 55-year-old woman with subacute onset of symmetrical stiffness and rigidity of the truncal
and proximal lower limb muscles that caused lower body bradykinesia, gait difficulties, and postural instability.
Diagnose of iPD was made and levodopa treatment was initiated but failed to provide beneficial effect. Six months
later, colon cancer was discovered and the patient underwent surgical procedure and chemotherapy with
capecitabine thereafter. Aggravation of stiffness, rigidity, and low back pain was observed after the first
chemotherapy cycle and capecitabine was discontinued. Furthermore, levodopa was slowly discontinued and low
dose of diazepam was administered which resulted in partial resolution of the patient’s symptoms.
Conclusion: Paraneoplastic SPS is rare disorder with clinical features resembling those of parkinsonian syndrome
and making the correct diagnosis remains a challenge. The diagnosis of parkinsonian syndrome should be re-examined
if subsequent examinations discover an associated malignant process. Although it remains unclear whether the patients
with history of SPS are at the greater risk for symptoms deterioration after administration of capecitabine, clinicians
should be aware of capecitabine side effects because recognition and appropriate management can prevent serious
adverse outcomes.Background
Stiff person syndrome (SPS) is a rare immune-mediated
disorder, which was first described by Moersch and
Woltman in 1956 [1]. Classic SPS is characterized by
mostly symmetric muscle stiffness and rigidity in axial and
proximal limb muscles, intermittent spasms, and pro-
nounced sensitivity to various external or emotional stimuli* Correspondence: sbadzek@gmail.com
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reproduction in any medium, provided the or[2,3]. Affection of lumbar paraspinal muscles causes typ-
ical lumbar hyperlordosis that persists in supine position
but diminishes during sleep. Impaired truncal and leg
mobility cause walking difficulties with a slow, stiff-legged
gait. Although the exact pathogenesis of SPS is still un-
clear, autoantibodies against glutamic acid decarboxylase
(GAD), the enzyme responsible for the synthesis of
γ-aminobutyric acid (GABA), are found in approximately
60% to 80% of SPS patients, thus suggesting important role
of immune system in the etiology of SPS [4,5]. In addition,
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SPS. It is assumed that decreased GABA-ergic inhib-
ition at brainstem and spinal cord level is responsible for
enhanced motor excitability [6]. SPS can occur also as a
paraneoplastic condition. Five percent of all SPS patients
are associated malignancies [7]. Association of colon can-
cer and SPS has rarely been reported. Here we report a
case of paraneoplastic SPS due to colon cancer that was
misdiagnosed as idiopathic Parkinson’s disease (iPD) with
a worsening of symptoms after inducing capecitabine
in therapy.
Case presentation
A 55-year-old woman was examined by a neurologist in
March 2011 because of subacute onset truncal and lower
limb stiffness, bradykinesia, and gait difficulties. Her past
medical history included arterial hypertension, hysterec-
tomy with bilateral adnexectomy due to cervical cancer
in 1999, consequent osteoporosis, and thyroidectomy
due to Hürthle cell adenoma in 2007. In September 2007
she was hospitalized because of lacunar ischemic stroke
in pons with mild gait ataxia as a sequel. There was no
prior history of parkinsonism, carbon monoxide poison-
ing, CNS infection, neuroleptic and toxin exposure. Rou-
tine laboratory tests, CBC, ESR, CRP, liver function tests,
electrolyte panel, coagulation profile, triiodothyronine,
thyroxine, and thyroid-stimulating hormone were within
normal limits. 123I-ioflupane (DaTSCAN) imaging was
also performed, and showed no signs of nigrostriatal
dopaminergic abnormalities. However, the diagnosis of
iPD was made. Rasagiline and levodopa were initiated
but failed to provide beneficial effect. On the contrary,
her symptoms worsened gradually. Six months later, sig-
moid colon cancer was discovered as an underlying cause
of newly discovered iron deficiency anemia. Left hemi-
colectomy was performed in September 2012. Pathological
review revealed colon adenocarcinoma, pT3N0M0, with
intermediate differentiation and microperforations as ad-
verse features, and adjuvant chemotherapy with cape-
citabine was started in September 2012. Aggravation of
stiffness, rigidity, and general mobility was observed after
the first cycle, and capecitabine was discontinued. The pa-
tient was referred to a Movement Disorders Centre for a
second opinion. Examination revealed stiffness and rigidity
of the truncal and proximal lower limb muscles and pro-
nounced lumbar hyperlordosis. Her gait was stiff-legged
and wide-based, but deductible only with the assistance of
another person. No signs of upper limb bradykinesia were
found. At the time, the patient was practically wheelchair-
bound. High suspicion of paraneoplastic SPS was made
and levodopa was slowly discontinued, while a dose of
10 mg diazepam BID was initiated. In addition, analysis of
serum anti-GAD antibody and onconeural antibodies (Hu,
Ri, Yo, Amphiphysin) was made, but was negative, andlevels of vitamin B12 and folic acid were within the normal
range. Therapy modification resulted in significant im-
provement of patient’s symptoms and daily functioning.
An additional movie file shows this in more detail (see
Additional file 1). As recommended by her oncologist,
adjuvant chemotherapy was continued for 6 months
total with simplified biweekly infusional 5-fluorouracil
plus leucovorin (sLV5FU2) according to recent NCCN
guidelines, without further neurological deterioration [8].
Conclusions
According to the clinical picture and course of the dis-
ease, our patient fulfilled criteria for paraneoplastic SPS,
although no onconeuronal antibodies were detected [9].
We find our case interesting for several reasons. First,
clinical features of paraneoplastic SPS can resemble
those of parkinsonian syndrome and making the correct
diagnosis can be challenging. It is hard to explain how
SPS has not been recognized earlier, but we speculate
that rarity of the condition could be attributed as
a most likely case scenario. Therefore, we would like
to emphasize that the diagnosis of iPD should be
re-examined in patients with subacute debut, rapid
progression of symptoms, lack of efficiency of dopamin-
ergic therapy, and atypical symptoms. Bearing in mind
that published data exist supporting the association of
seronegative SPS and cancer in about 25% of cases, al-
though with no causal relationship proven, in such pa-
tients additional diagnostic procedures are required and
possible underlying malignancies should be excluded
[10]. In addition, the diagnosis of parkinsonian syndrome
should be re-examined if subsequent examinations dis-
cover an associated malignant process. Second, para-
neoplastic SPS usually occur in the presence of breast
cancer, small cell lung carcinoma, thymoma, and Hodgkin’s
lymphoma, and so far, we found only one report simi-
lar to ours [11]. This association should be kept in mind,
because early-stage tumor detection enables appropri-
ate treatment. And third, clinical observation of ag-
gravation of stiffness, rigidity, and low back pain with
capecitabine therapy should not be ignored. Low back
pain is known to be a possible side effect of capeci-
tabine, but whether the patients with history of SPS are
at greater risk for symptom deterioration remains un-
clear, and more reports are needed for providing any
conclusion. A possible explanation could be the interaction
of capecitabine and its metabolites with inhibitory GABA-
ergic pathway.
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